Homocyst(e)ine and stroke

Seminars in Neurology

Volumn 26, Issue 1, 2006, Pages 24-32

  Furie, Karen L ^a   Kelly, Peter J ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Folate; Genetics; Homocysteine; Vitamins

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

AMINO ACID METABOLISM; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; HEART INFARCTION; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTEMATIC REVIEW; UNITED STATES; VEIN THROMBOSIS; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

EID: 33244459375     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-933306     Document Type: Review

References (107)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969;56:111-128
2. Fowler B. Disorders of homocysteine metabolism. J Inherit Metab Dis 1997;20:270-285
3. Welch GN. Hyperhomocyst(e)inemia and atherothrombosis. Am NY Acad Sci 1997;811:48-58
4. Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-715
5. Clarke R, Daly L, Naughten E, Calahane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155
6. Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia- a possible risk factor for arteriosderotic cerebrovascular disease. Stroke 1984;15:1012-1016
7. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulphydryl-containing amino acids in patients with cerebral infarction and in hypertensive patients. Atherosclerosis 1989;79:139-146
8. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21:572-576
9. Brattstrom L, Lindgren A, Israelsson B, et al. Hyperhomocysteinemia in stroke: prevalence, causes and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992; 22:214-221
10. Ubbink JB. Assay methods for the measurement of total homocyst(e)ine in plasma. Semin Thromb Hemost 2000;26: 233-241
11. El-Sammak M, Kandil M, El-Hifni S, Hosni R, Ragab M. Elevated plasma homocysteine is positively associated with age independent of C677T mutation of the methylenetetrahydrofolate reductase gene in selected Egyptian subjects. Int J Med Sci 2004;1:181-192
12. Bruschi F, Daguati R, Parazzini F, et al. Age, menopausal status and homocysteine levels in women around menopause. Eur J Obstet Gynecol Reprod Biol 2005;120:195-197
13. Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999;159: 38-44
14. Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998;29:2478-2483
15. Lindgren A, Brattstrom L, Norving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26: 795-800
16. Meiklejohn DJ, Vickers MA, Dijkhuisen R, Greaves M. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001;32:57-62
17. Howard VJ, Sides EG, Newman GC, et al. Stability of Plasma Homocyst(e)ine in Acute Stroke Patients (SHASP) Study Investigators. Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke 2002;33:473-478
18. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-741
19. Ratnoff OD. Activation of Hageman factor by L-homocystine. Science 1968;162:1007-1009
20. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparin sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993;92:1381-1386
21. Ratnoff OD. Activation of Hageman factor by L-homocystine. Science 1968;162:1007-1009
22. Nappo F, DeRosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281:2113-2118
23. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997;17:1947-1953
24. Mercié P, Seigneur M, Conri C, Boisseau MR. Hyperhomocysteinemia and endothelial dysfunction in peripheral arterial disease. Thromb Res 1999;93:97-99
25. Freyburger G, Labrouche S, Sassoust G, Rouanet F, Javorschi S, Parrot F. Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. Thromb Haemost 1997;77:466-471
26. Tsai J-C, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373
27. Ogawa M, Abe S, Saigo M, et al. Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age. Thromb Res 2003;109:253-258
28. Al-Obaidi MK, Philippou H, Stubbs PJ, et al. Relationships between homocysteine, factor Vila, and thrombin generation in acute coronary syndromes. Circulation 2000; 101:372-377
29. Kyrle PA, Stümpften A, Hirschl M, et al. Levels of prothrombin fragment F1 + 2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. Thromb Haemost 1997;78:1327-1331
30. Hajjar KA, Mauri L, Jacovina AT, et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998;273:9987-9993
31. Kristensen B, Malm J, Nilsson TK, et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Stroke 1999;30:974-980
32. Dusitanond P, Eikelboom JW, Hankey GJ, et al. Homocysteine-lowering treatment with folk acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. Stroke 2005;36:144-146
33. Vermeulen EG, Rauwerda JA, van den Berg M, et al. Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial. Eur J Clin Invest 2003;33:209-215
34. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057
35. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19
36. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25:1924-1930
37. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-1398
38. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-5-75
39. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693-2698
40. den Heijer M, Brouwer IA, Bos GMJ, et al. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers. Arteriosder Thromb Vasc Biol 1998;18:356-361
41. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340: 1449-1454
42. Anonymous. Is vitamin B6 an antithrombotic agent? Lancet 1981;1:1299-1300
43. Chi MS. Vitamin B6 in cholesterol metabolism. Nutr Res 1984;4:359-362
44. Rinehart JF, Greenberg LD. Arteriosclerotic lesions in pyridoxine-deficient monkeys. AmJ Path 1949;25:481-491
45. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818
46. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999;281: 1817-1821
47. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol 2000;20:1047-1051
48. Kelly PJ, Shih VE, Kistler JP, et al. Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folk acid grain fortification. Stroke 2003;34:e51-e54
49. Friso S, Jacques PF, Wilson PWF, Rosenberg IH, Selhub J. Low circulating vitamin B6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001;103:2788-2791
50. Friso S, Jacques PF, Wilson PWF, Rosenberg IH, Selhub J. Low circulating vitamin B6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001;103:2788-2791
51. Roubenoff R, Roubenoff RA, Selhub J, et al. Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation. Arthritis Rheum 1995;38:105-109
52. Rail LC, Meydani SN. Vitamin B6 and immune competence. Nutr Rev 1993;51:217-225
53. Kelly PJ, Kistler JP, Shih VE, et al. Inflammation, homocysteine, and vitamin B6 status after ischemic stroke. Stroke 2004;35:12-15
54. Goldstein L, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001;32:280-299
55. de Franchis R, Kozich V, McInnes R, Kraus JP. Identical genotype in a sibship with different, homocystinuric phenotype: identification of 3 mutations in cystathionine β-synthase using an improved bacterial expression system. Hum Mol Genet 1994;3:1103-1108
56. Kozich V, de Franchis R, Kraus JP. Molecular defect in a patient with pyridoxine-responsive homocystinuria. Hum Mol Genet 1993;2:815-816
57. Sperandeo MP, Candito M, Sebastio G, et al. Homocysteine response to methionine challenge in four obligate heterozyotes for homocystinuria and relationship with cystathionine beta-synthase mutations. J Inherit Metab Dis 1996; 19:351-356
58. 6 nonresponsive homocystinuria. Hum Mol Genet 1994;3:1883-1886
59. Shih VE, Fringer JM, Mandell R, et al. A missense mutation (I278T) in the cystathionine beta-synthase gene prevalent in pyridoxine-responsive homocystinuria and associated with mild clinical phenotype. Am J Hum Genet 1995;57:34-39
60. Kluijtmans LA, Blom HJ, Boers GH, van Oost BA, Trijbels FJ, van den Heuvel LP. Two novel missense mutations in the cystathionine beta-synthase gene in homocystinuric patients. Hum Genet 1995;96:249-250
61. Kruger WD, Cox DR. A yeast assay for functional detection of mutations in the human cystathionine beta-synthase gene. Hum Mol Genet 1995;4:1155-1161
62. Kozich V, Kraus JP. Screening for mutations by expressing patient cDNA segments in E. coli: homocystinuria due to cystathionine beta-synthase deficiency. Hum Mutat 1992;1:113-123
63. Sperandeo MP, Panico M, Pepe A, et al. Molecular analysis of patients affected by homocystinuria due to cystathionine beta-synthase deficiency: report of a new mutation in exon 8 and a deletion in intron 11. J Inherit Metab Dis 1995;18: 211-214
64. Hu FL, Gu Z, Kozich V, Kraus JP, Ramesh V, Shih VE. Molecular basis of cystathionine beta-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. Hum Mol Genet 1993;2:1857-1860
65. Tsai MY, Hanson NQ, Bignell MK, Schwichtenberg KA. Simultaneous detection and screening of T833C and G919A mutations of the cystathionine beta-synthase gene by single strand conformational polymorphism. Clin Biochem 1996; 29:473-477
66. Dawson PA, Cox AJ, Emmerson BT, Dudman NP, Kraus JP, Gordon RB. Characterisation of five missense mutations in the cystathionine beta-synthase gene from three patients with B6-nonresponsive homocystinuria. Eur J Hum Genet 1997;5:15-21
67. Kraus JP. Molecular basis of phenotype expression in homocystinuria. J Inherit Metab Dis 1994;17:383-390
68. Aral B, Coude M, London J, et al. Two novel mutations (K384E and L539S) in the C-terminal moiety of the cystathionine beta-synthase protein in two French pyridoxine-responsive homocystinuria patients. Hum Mutat 1997; 9:81-82
69. Kluijtmans LA, Boers GH, Stevens EM, et al. Defective cystathionine beta-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. J Clin Invest 1996;98:285-289
70. Sebastio G, Sperandeo MP, Panico M, de Franchis R, Kraus JP, Andria G. The molecular basis of homocystinuria due to cystathionine beta-synthase deficiency in Italian families, and report of four novel mutations. Am J Hum Genet 1995;56: 1324-1333
71. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocystinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988;43:414-421
72. Kang SS, Wong PWK, Zhou J, et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988;37:611-613
73. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113
74. Kittner SJ, Giles WH, Macko RF, et al. Homocyst(e)ine and risk of cerebral infarction in a biracial population: the stroke prevention in young women study. Stroke 1999;30:1554-1560
75. Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C → T mutation of the methylenete-trahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998;79:119-121
76. De Franchis R, Mancini FP, D'Angelo A, et al. Elevated total plasma homocysteine and 677C T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 1996;59:262-264
77. Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase (MTHFR) gene with plasma homocysteine in patients with premature coronary artery disease. Arteriosder Thromb Vasc Biol 1997;17:569-573
78. Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary artery disease: evidence for a common gene mutation. Circulation 1996;94:2154-2158
79. Kluijtmans LA, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41
80. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenete-trahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis 1996;121:293-294
81. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenete-trahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9
82. Rozen R. Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med 1996;19: 171-178
83. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997;78:523-526
84. Harmon DL, Woodside JV, Yarnell JWG, et al. The common thermolabile variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. QJM 1996;89:571-577
85. De Franchis R, Mancini FP, D'Angelo A, et al. Elevated total plasma homocysteine and 677C T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 1996;59:262-264
86. Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase (MTHFR) gene with plasma homocysteine in patients with premature coronary artery disease. Arteriosder Thromb Vasc Biol 1997;17:569-573
87. Sacchi E, Taglibue L, Duca F, Mannuci PM. High frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in Northern Italy. Thromb Haemost 1997;78:963-964
88. Oakley GP Jr. Eat right and take a multivitamin. N Engl J Med 1998;338:1060-1061
89. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-1015
90. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomization. Lancet 2005;365:224-232
91. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202
92. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke 2005;36:1581-1587
93. Souto JC, Blanco-Vaca F, Soria JM, et al. A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project. Am J Hum Genet 2005;76:925-933
94. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-291
95. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993;87:1107-1113
96. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999;131:352-355
97. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition Examination Survey, 1988-1994. Stroke 1998; 29:2473-2477
98. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000;31:1069-1075
99. Tan NC-K, Venketasubramanian N, Saw SM, Tjia HTL. Hyperhomocyst(e)inemia and risk of ischemic stroke among young Asian adults. Stroke 2002;33:1956-1962
100. Van Der Meer I, de Maat MP, Hak AE, et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree. The Rotterdam study. Stroke 2002;33:2750-2755
101. Ay H, Arsara EM, Tokgozoghi SL, Ozer N, Saribas O. Hyperhomocysteinemia is associated with left atrial thrombus in stroke patients with nonvascular atrial fibrillation. Stroke 2003;34:909-912
102. Gallai V, Caso V, Paciaroni M, et al. Mild hyperhomocyst(e)inemia: a possible risk factor for cervical artery dissection. Stroke 2001;32:714-718
103. Pezzini A, Del Zotto E, Archetti S, et al. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. Stroke 2002;33:664-669
104. Jacques PF, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folk acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340: 1449-1454
105. Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with folic acid based supplements: metaanalysis of randomised trials. BMJ 1998;316:894-898
106. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575
107. VITATOPS Trial Study Group. Homocysteine VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and design of an international large, simple, randomised trial of homocysteine lowering multivitamin therapy in patients with recent transient ischemic attack or stroke. Cerebrovasc Dis 2002;13:120-126